GE HealthCare signed a cash agreement to acquire SOFIE Biosciences from Trilantic North America for 945 million dollars. SOFIE operates a US manufacturing network for radioactive products used in PET imaging. The acquisition would add 15 manufacturing sites and 21 cyclotrons. GE HealthCare expects completion in the first half of 2027, subject to regulatory approvals and other closing conditions.
GE HealthCare agreed to buy SOFIE Biosciences, a US contract manufacturer of radioactive products used in medical imaging, for 945 million dollars in cash. The October 5 announcement sets out a purchase of its manufacturing network for positron emission tomography, or PET. The planned acquisition would strengthen the company’s supply chain for products that need rapid delivery from local production sites to patients.[1], [2]
SOFIE operates fifteen US contract manufacturing sites with twenty-one cyclotrons, the accelerators used in radiopharmaceutical production. It also has a separate development and manufacturing site focused on theranostics, which combines diagnosis and treatment. F18-labelled PET radiopharmaceuticals have a half-life of 110 minutes. GE HealthCare highlights the role of local production in the time-critical final delivery stage.[1]
SOFIE already manufactures GE HealthCare’s Flyrcado product. After closing, it is expected to keep serving existing customers as an independent manufacturing partner, including other radiopharmaceutical providers. GE HealthCare intends to expand access to existing F18 products through both SOFIE and its other US manufacturing partners. Its diagnostic agents supported 140 million procedures in 2025.[1]
The seller is Trilantic North America. GE HealthCare expects the transaction to close in the first half of 2027, subject to regulatory approvals and other closing conditions. SOFIE would then join its Pharmaceutical Diagnostics segment. Segment president and chief executive Kevin O’Neill expects SOFIE to grow at low double-digit rates within the group. The company also expects the deal to contribute to revenue growth, adjusted operating margin and adjusted earnings per share in the first full year of ownership.[1]
SOFIE’s FAPI-74 PET radiotracer, an F18 fibroblast activation protein inhibitor, is in phase-three clinical development. GE HealthCare already holds rights outside the United States. SOFIE co-founder, president and chief executive Patrick Phelps said demand for new diagnostic and therapeutic products was increasing the need for manufacturing capacity. The announcement does not describe the product as approved.[1]
